Home
Resources
Diseases
Compendium
Training
Evaluation
The Tool
The Tutorial
SYSVAC
About
Registry
E-learning courses
News
Webinars
Network
Steering Committee
Vision and Mission
Map
Meetings
Partners
Join us
Home
Resources
Resources
Type of publications
Guidelines (30)
NITAG documentation (1591)
Reports (55)
SAGE documentation (218)
Scientific publications (112)
Systematic reviews (SYSVAC) (2750)
Regions
Africa (267)
Americas (762)
Eastern Mediterranean (48)
Europe (704)
South-East Asia (78)
Western Pacific (196)
Diseases
Chikungunya (9)
Cholera (33)
COVID-19 (1481)
Cytomegalovirus (1)
Dengue (39)
Diphtheria (79)
Ebola (16)
Escherichia coli (ETEC) (2)
Haemophilus influenzae type B (66)
Hepatitis A (63)
Hepatitis B (153)
Hepatitis C (4)
Hepatitis E (5)
Herpes simplex (1)
Herpes zoster (66)
HIV / AIDS (10)
Human papillomavirus (HPV) (472)
Influenza (573)
Japanese encephalitis (34)
Lyme disease, Borreliosis (1)
Malaria (27)
Measles (128)
Meningococcal disease (145)
Mpox (55)
Mumps (46)
Pertussis (104)
Pneumococcal disease (266)
Poliomyelitis (84)
Q fever (1)
Rabies (28)
Rotavirus (115)
RSV (Respiratory syncytial virus) (47)
Rubella (64)
Salmonella (2)
Shigella (1)
Smallpox (16)
Streptococcus group B (6)
Tetanus (59)
Tick-borne encephalitis (12)
Tuberculosis (73)
Typhoid (23)
Varicella (69)
Yellow fever (42)
Zika (1)
Show more
4756 results found
2017
∙
STIKO
Background paper to the decision not to recommend a standard vaccination with the live attenuated herpes zoster vaccine for the elderly in Germany
2017
∙
SAGE
Evidence to recommendation table (duration)
2017
∙
SAGE
Evidence to recommendation table (birth dose)
2017
∙
SAGE
Hepatitis B vaccines: WHO position paper
2017
∙
SAGE
Effectiveness of measles vaccine in young children and adolescents
2017
∙
SAGE
Should SAGE recommend the removal of the criterion that MCV2 only be given if MCV1 coverage is >80% for the introduction of routine measles second dose as stated in the 2009 measles vaccine position paper?
2017
∙
SAGE
Systematic literature review and meta-analyses of the benefits and risks of measles vaccination below 6 months of age
2017
∙
SAGE
Safety of the measles vaccine in young children and adolescents
2017
∙
SAGE
Duration of protection following measles immunization
2017
∙
SAGE
Should an additional dose of measles-containing vaccine be recommended for HIV-infected adolescents and adults?
Home
Resources
Diseases
Compendium
Training
Evaluation
SYSVAC
News
Webinars
Network
Sign in / Register